Structure Therapeutics Inc. (GPCR)

NGM – Цена в реальном времени. Валюта: USD

37.84

-0.48 (-1.25%)

При закрытии: May 12, 2026, 4:00 PM EDT

07.05.2026

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Reported positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially comparable efficacy to injectable GLP1-RAs Data from ACCESS OLE expected in Q3 2026; Data from the Body Composition and Type 2 Diabetes/Obesity data expected in Q4 2026 Positive end-of-Phase 2 feedback received from FDA; aleniglipron Phase 3 initiation on track for Q3 2026 Initial data from Phase 1 single ascending dose (SAD) study of oral small molecule amylin receptor agonist ACCG-2671 and initiation of multiple ascending dose (MAD) study expected in Q3 2026; Phase 1 initiation of second oral amylin candidate ACCG-3535 expected in Q4 2026 Aleniglipron, amylin and combination data to be presented at the American Diabetes Association (ADA) 86th Scientific Sessions in June 2026 Cash, cash equivalents and short-term investments of $1.5 billion as of March 31, 2026, expected to provide cash runway through the end of 2028 SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. “With positive end of Phase 2 feedback received from the FDA for aleniglipron, we are well positioned to start our Phase 3 registrational program for chronic weight management in the third quarter,” said Raymond Stevens, Ph.D.

27.04.2026

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced multiple presentations at the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5–8, 2026 in New Orleans, Louisiana. The presentations include an oral presentation on the ACCESS Phase 2b clinical trial of aleniglipron.

17.04.2026

3 Ways to Invest in the Growing GLP-1 Weight Loss Market

Weight loss drugs are big business, with the GLP-1 receptor agonist market expected to nearly triple in size to $185 billion by 2033, a compound annual growth rate of about 12.4%. Although increasingly a global medical phenomenon, the bulk of the market still exists in the United States, and domestic investors can get in on the action by targeting companies that manufacture these powerful drugs.

14.04.2026

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the appointment of Matthew Lang, J.D. as Chief Operating Officer and General Counsel. Mr. Lang joins Structure Therapeutics with more than fifteen years of executive leadership experience across global biopharmaceutical organizations, with deep expertise spanning legal, corporate strategy, compliance, risk management, and business development.

08.04.2026

Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy Meets Biased-Agonism Safety Moat

Structure Therapeutics (GPCR) is initiated with a BUY rating and $110 price target, reflecting a 101% upside from current levels. Aleniglipron, GPCR's oral GLP-1 agonist, demonstrated 16.3% placebo-adjusted weight loss at 44 weeks with superior safety and manufacturing cost advantages. GPCR's $1.4B cash position provides runway through 2028 and a valuation floor of $23.10 in a bear scenario.

01.04.2026

What's Going On With Structure Therapeutics Stock On Wednesday?

• What's the outlook for GCPR shares?

01.04.2026

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the next transformative asset.

Видео

15.01.2026

Positive

Structure CEO Ray Stevens talks its obesity drug portfolio

10.11.2025

Neutral

Final Trade: UBER, CRWV, GPCR, DIS

Пресс-релизы

07.05.2026

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

14.04.2026

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

16.03.2026

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral GLP-1RAs and comparable efficacy to injectable GLP1-RAs

26.02.2026

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks

Structure Therapeutics Inc. (GPCR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Structure Therapeutics Inc. (GPCR)

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

3 Ways to Invest in the Growing GLP-1 Weight Loss Market

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy Meets Biased-Agonism Safety Moat

What's Going On With Structure Therapeutics Stock On Wednesday?

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

Видео

Пресс-релизы

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

3 Ways to Invest in the Growing GLP-1 Weight Loss Market

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy Meets Biased-Agonism Safety Moat

What's Going On With Structure Therapeutics Stock On Wednesday?

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

Видео

Пресс-релизы

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Search stocks

Structure Therapeutics Inc. (GPCR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Structure Therapeutics Inc. (GPCR)

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

3 Ways to Invest in the Growing GLP-1 Weight Loss Market

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy Meets Biased-Agonism Safety Moat

What's Going On With Structure Therapeutics Stock On Wednesday?

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

Видео

Пресс-релизы

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

3 Ways to Invest in the Growing GLP-1 Weight Loss Market

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

Structure Therapeutics: The Oral Obesity Inflection, Best-In-Class Efficacy Meets Biased-Agonism Safety Moat

What's Going On With Structure Therapeutics Stock On Wednesday?

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

Видео

Пресс-релизы

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights